As of April 24, 2022, the coronavirus (COVID-19) recovery rate in Morocco stood at 98.6 percent. The rate of recovery has remained above 80 percent since December 2020. The highest rates were recorded in December 2021, while the lowest was in August 2021.

As of May 2, 2023, the outbreak of the coronavirus disease (COVID-19) had been confirmed in almost every country in the world. The virus had infected over 687 million people worldwide, and the number of deaths had reached almost 6.87 million. The most severely affected countries include the U.S., India, and Brazil.

COVID-19: background information COVID-19 is a novel coronavirus that had not previously been identified in humans. The first case was detected in the Hubei province of China at the end of December 2019. The virus is highly transmissible and coughing and sneezing are the most common forms of transmission, which is similar to the outbreak of the SARS coronavirus that began in 2002 and was thought to have spread via cough and sneeze droplets expelled into the air by infected persons.

Naming the coronavirus disease Coronaviruses are a group of viruses that can be transmitted between animals and people, causing illnesses that may range from the common cold to more severe respiratory syndromes. In February 2020, the International Committee on Taxonomy of Viruses and the World Health Organization announced official names for both the virus and the disease it causes: SARS-CoV-2 and COVID-19, respectively. The name of the disease is derived from the words corona, virus, and disease, while the number 19 represents the year that it emerged.

As of May 2, 2023, the coronavirus disease (COVID-19) had been confirmed in almost every country and territory around the world. There had been roughly 687 million cases and 6.86 million deaths.

Vaccine approval in the United States The United States has recorded more coronavirus infections and deaths than any other country in the world. The regulatory agency in the country authorized three COVID-19 vaccines for emergency use. Both the Pfizer-BioNTech and Moderna vaccines were approved in December 2020, while the Johnson & Johnson vaccine was approved in February 2021. As of April 26, 2023, the number of COVID-19 vaccine doses administered in the U.S. had reached 675 million.

The difference between vaccines and antivirals Medications can help with the symptoms of viruses, but it is the role of the immune system to take care of them over time. However, the use of vaccines and antivirals can help the immune system in doing its job. The most tried and tested vaccine method is to inject an inactive or weakened form of a virus, encouraging the immune system to produce protective antibodies. The immune system keeps the virus in its memory, and if the real one appears, the body will recognize it and attack it more efficiently. Antivirals are designed to help target viruses, limiting their ability to reproduce and spread to other cells. They are used by patients who are already infected by a virus and can make the infection less severe.

Methodology for predicting hospital admissions and evaluating recovery rates for coronavirus disease in Japan

The COVID-19 Vulnerability and Recovery Index uses Tract and ZIP Code-level data* to identify California communities most in need of immediate and long-term pandemic and economic relief. Specifically, the Index is comprised of three components — Risk, Severity, and Recovery Need with the last scoring the ability to recover from the health, economic, and social costs of the pandemic. Communities with higher Index scores face a higher risk of COVID-19 infection and death and a longer uphill economic recovery. Conversely, those with lower scores are less vulnerable.

The Index includes one overarching Index score as well as a score for each of the individual components. Each component includes a set of indicators we found to be associated with COVID-19 risk, severity, or recovery in our review of existing indices and independent analysis. The Risk component includes indicators related to the risk of COVID-19 infection. The Severity component includes indicators designed to measure the risk of severe illness or death from COVID-19. The Recovery Need component includes indicators that measure community needs related to economic and social recovery. The overarching Index score is designed to show level of need from Highest to Lowest with ZIP Codes in the Highest or High need categories, or top 20th or 40th percentiles of the Index, having the greatest need for support.

The Index was originally developed as a statewide tool but has been adapted to LA County for the purposes of the Board motion. To distinguish between the LA County Index and the original Statewide Index, we refer to the revised Index for LA County as the LA County ARPA Index.

*Zip Code data has been crosswalked to Census Tract using HUD methodology

Indicators within each component of the LA County ARPA Index are:Risk: Individuals without U.S. citizenship; Population Below 200% of the Federal Poverty Level (FPL); Overcrowded Housing Units; Essential Workers Severity: Asthma Hospitalizations (per 10,000); Population Below 200% FPL; Seniors 75 and over in Poverty; Uninsured Population; Heart Disease Hospitalizations (per 10,000); Diabetes Hospitalizations (per 10,000)Recovery Need: Single-Parent Households; Gun Injuries (per 10,000); Population Below 200% FPL; Essential Workers; Unemployment; Uninsured PopulationData are sourced from US Census American Communities Survey (ACS) and the OSHPD Patient Discharge Database. For ACS indicators, the tables and variables used are as follows:

Indicator

ACS Table/Years

Numerator

Denominator

Non-US Citizen

B05001, 2019-2023

b05001_006e

b05001_001e

Below 200% FPL

S1701, 2019-2023

s1701_c01_042e

s1701_c01_001e

Overcrowded Housing Units

B25014, 2019-2023

b25014_006e + b25014_007e + b25014_012e + b25014_013e

b25014_001e

Essential Workers

S2401, 2019-2023

s2401_c01_005e + s2401_c01_011e + s2401_c01_013e + s2401_c01_015e + s2401_c01_019e + s2401_c01_020e + s2401_c01_023e + s2401_c01_024e + s2401_c01_029e + s2401_c01_033e

s2401_c01_001

Seniors 75+ in Poverty

B17020, 2019-2023

b17020_008e + b17020_009e

b17020_008e + b17020_009e + b17020_016e + b17020_017e

Uninsured

S2701, 2019-2023

s2701_c05_001e

NA, rate published in source table

Single-Parent Households

S1101, 2019-2023

s1101_c03_005e + s1101_c04_005e

s1101_c01_001e

Unemployment

S2301, 2019-2023

s2301_c04_001e

NA, rate published in source table

The remaining indicators are based data requested and received by Advancement Project CA from the OSHPD Patient Discharge database. Data are based on records aggregated at the ZIP Code level:

Indicator

Years

Definition

Denominator

Asthma Hospitalizations

2017-2019

All ICD 10 codes under J45 (under Principal Diagnosis)

American Community Survey, 2015-2019, 5-Year Estimates, Table DP05

Gun Injuries

2017-2019

Principal/Other External Cause Code "Gun Injury" with a Disposition not "Died/Expired". ICD 10 Code Y38.4 and all codes under X94, W32, W33, W34, X72, X73, X74, X93, X95, Y22, Y23, Y35 [All listed codes with 7th digit "A" for initial encounter]

American Community Survey, 2015-2019, 5-Year Estimates, Table DP05

Heart Disease Hospitalizations

2017-2019

ICD 10 Code I46.2 and all ICD 10 codes under I21, I22, I24, I25, I42, I50 (under Principal Diagnosis)

American Community Survey, 2015-2019, 5-Year Estimates, Table DP05

Diabetes (Type 2) Hospitalizations

2017-2019

All ICD 10 codes under E11 (under Principal Diagnosis)

American Community Survey, 2015-2019, 5-Year Estimates, Table DP05

For more information about this dataset, please contact egis@isd.lacounty.gov.

Since the spread of the coronavirus (COVID-19) in Italy started in February 2020, the number of cases has increased daily. However, the vast majority of people who contracted the virus have recovered. As of January 8, 2025, the number of individuals who recovered from coronavirus in Italy reached over 26.5 million. Conversely, the number of deaths also kept increasing, reaching over 198.6 thousand. When looking at the regional level, the region with the highest number of recoveries was Lombardy. The region, however, registered the highest number of coronavirus cases in the country. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

BackgroundThymosin alpha 1 (Tα1) is widely used to treat patients with COVID-19 in China; however, its efficacy remains unclear. This study aimed to explore the efficacy of Tα1 as a COVID-19 therapy.MethodsWe performed a multicenter cohort study in five tertiary hospitals in the Hubei province of China between December 2019 and March 2020. The patient non-recovery rate was used as the primary outcome.ResultsAll crude outcomes, including non-recovery rate (65/306 vs. 290/1,976, p = 0.003), in-hospital mortality rate (62/306 vs. 271/1,976, p = 0.003), intubation rate (31/306 vs. 106/1,976, p = 0.001), acute respiratory distress syndrome (ARDS) incidence (104/306 vs. 499/1,976, p = 0.001), acute kidney injury (AKI) incidence (26/306 vs. 66/1,976, p < 0.001), and length of intensive care unit (ICU) stay (14.9 ± 12.7 vs. 8.7 ± 8.2 days, p < 0.001), were significantly higher in the Tα1 treatment group. After adjusting for confounding factors, Tα1 use was found to be significantly associated with a higher non-recovery rate than non-Tα1 use (OR 1.5, 95% CI 1.1–2.1, p = 0.028). An increased risk of non-recovery rate associated with Tα1 use was observed in the patient subgroups with maximum sequential organ failure assessment (SOFA) scores ≥2 (OR 2.0, 95%CI 1.4–2.9, p = 0.024), a record of ICU admission (OR 5.4, 95%CI 2.1–14.0, p < 0.001), and lower PaO2/FiO2 values (OR 1.9, 95%CI 1.1–3.4, p = 0.046). Furthermore, later initiation of Tα1 use was associated with a higher non-recovery rate.ConclusionTα1 use in COVID-19 patients was associated with an increased non-recovery rate, especially in those with greater disease severity.

BEA has been researching the use of card transaction data as an early barometer of spending in the United States. Since the emergence of COVID-19, dramatic and fast-moving changes to the U.S. economy have increased the public and policymakers' need for more frequent and timely economic data. In response, BEA is presenting these estimates using daily payment card data to measure the effects of the pandemic on spending, updated approximately every two weeks. Note that these payment card transactions are not necessarily representative of total spending in an industry and the data have other limitations, described below. The estimates in these charts and tables are not a substitute for BEA's monthly and quarterly official data, which are grounded in well-tested and proven methodologies. An event study methodology is used to estimate the difference (in percentage points) in spending from the typical level (relative to the day of week, month, and annual trends) prior to the pandemic declared by the World Health Organization on March 11, 2020.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases among people who received additional or booster doses were reported from 31 jurisdictions; 30 jurisdictions also reported data on deaths among people who received one or more additional or booster dose; 28 jurisdictions reported cases among people who received two or more additional or booster doses; and 26 jurisdictions reported deaths among people who received two or more additional or booster doses. This list will be updated as more jurisdictions participate. Incidence rate estimates: Weekly age-specific incidence rates by vaccination status were calculated as the number of cases or deaths divided by the number of people vaccinated with a primary series, overall or with/without a booster dose (cumulative) or unvaccinated (obtained by subtracting the cumulative number of people vaccinated with a primary series and partially vaccinated people from the 2019 U.S. intercensal population estimates) and multiplied by 100,000. Overall incidence rates were age-standardized using the 2000 U.S. Census standard population. To estimate population counts for ages 6 months through 1 year, half of the single-year population counts for ages 0 through 1 year were used. All rates are plotted by positive specimen collection date to reflect when incident infections occurred. For the primary series analysis, age-standardized rates include ages 12 years and older from April 4, 2021 through December 4, 2021, ages 5 years and older from December 5, 2021 through July 30, 2022 and ages 6 months and older from July 31, 2022 onwards. For the booster dose analysis, age-standardized rates include ages 18 years and older from September 19, 2021 through December 25, 2021, ages 12 years and older from December 26, 2021, and ages 5 years and older from June 5, 2022 onwards. Small numbers could contribute to less precision when calculating death rates among some groups. Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent incidence and death rates from growing unrealistically large due to potential overestimates of vaccination coverage. Incidence rate ratios (IRRs): IRRs for the past one month were calculated by dividing the average weekly incidence rates among unvaccinated people by that among people vaccinated with a primary series either overall or with a booster dose. Publications: Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1284–1290. Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–138. Johnson AG, Linde L, Ali AR, et al. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022. MMWR Morb Mortal Wkly Rep 2023;72:145–152. Johnson AG, Linde L, Payne AB, et al. Notes from the Field: Comparison of COVID-19 Mortality Rates Among Adults Aged ≥65 Years Who Were Unvaccinated and Those Who Received a Bivalent Booster Dose Within the Preceding 6 Months — 20 U.S. Jurisdictions, September 18, 2022–April 1, 2023. MMWR Morb Mortal Wkly Rep 2023;72:667–669.

United States recorded 16306656 Coronavirus Recovered since the epidemic began, according to the World Health Organization (WHO). In addition, United States reported 797346 Coronavirus Deaths. This dataset includes a chart with historical data for the United States Coronavirus Recovered.

In a May 2020 survey, 44 percent of surveyed CIOs said that they expect a U-Shaped economic recovery from COVID-19, with declines in revenue for the second and third quarters of 2020 followed by growth in 2021.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Fact and Figures page.

Model parameters, their computed values and forecasts for the Hubei province under two scenarios: (I) using the exact values of confirmed cases or (II) using estimations for infected and recovered (twenty and forty times the number of confirmed cases, respectively).

1. COVID-19 confirmed case, death, case fatality rate and cumulative recovery rate data of Bangladesh
2. COVID-19 virus Genomics data

Results of the prediction of number of confirmed cases on February 3rd.

BackgroundThe COVID-19 pandemic has resulted in significant morbidity and mortality worldwide, with cytokine storm leading to exaggerating immune response, multi-organ dysfunction and death. Melatonin has been shown to have anti-inflammatory and immunomodulatory effects and its effect on COVID-19 clinical outcomes is controversial. This study aimed to conduct a meta-analysis to evaluate the impact of melatonin on COVID-19 patients.MethodsPubMed, Embase, and Cochrane Central Register of Controlled Trials were searched without any language or publication year limitations from inception to 15 Nov 2022. Randomized controlled trials (RCTs) using melatonin as therapy in COVID-19 patients were included. The primary outcome was mortality, and the secondary outcomes included were the recovery rate of clinical symptoms, changes in the inflammatory markers like C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and neutrophil to lymphocyte ratio (NLR). A random-effects model was applied for meta-analyses, and further subgroup and sensitivity analyses were also conducted.ResultsA total of nine RCTs with 718 subjects were included. Five studies using melatonin with the primary outcome were analyzed, and the pooled results showed no significant difference in mortality between melatonin and control groups with high heterogeneity across studies identified (risk ratio [RR] 0.72, 95% confidence interval [CI] 0.47–1.11, p = 0.14, I2 = 82%). However, subgroup analyses revealed statistically significant effects in patients aged under 55 years (RR 0.71, 95% CI 0.62–0.82, p < 0.01) and in patients treated for more than 10 days (RR 0.07, 95% CI 0.01–0.53, p = 0.01). The recovery rate of clinical symptoms and changes in CRP, ESR, and NLR were not statistically significant. No serious adverse effects were reported from melatonin use.ConclusionIn conclusion, based on low certainty of evidence, the study concluded that melatonin therapy does not significantly reduce mortality in COVID-19 patients, but there are possible benefits in patients under 55 years or treated for more than 10 days. With a very low certainty of evidence, we found no significant difference in the recovery rate of COVID-19 related symptoms or inflammatory markers in current studies. Further studies with larger sample sizes are warranted to determine the possible efficacy of melatonin on COVID-19 patients.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42022351424.

COVID-19 pandemic caused significant disruptions in healthcare services, with previous studies estimated that the early months of the pandemic led to a substantial decline in new prescriptions for hypercholesterolemia and hypertension. The long-term recovery of healthcare systems in addressing these gaps remains uncertain. We aimed to assess the recovery of the healthcare system in Scotland regarding the initiation of treatments for hypercholesterolemia and hypertension post-COVID-19 pandemic.This retrospective cohort study analysed prescription data from January 2020 to December 2022 in Scotland, as well as In-hours encounters with general practitioners. Incident prescribing patterns for drugs used in the treatment of hypercholesterolemia and hypertension were compared against pre-pandemic averages from 2018 to 2019. Data were stratified by health regions and socioeconomic status.New treatment initiations for drugs used in the treatment of hypercholesterolemia and hypertension significantly increased from mid-2021 onwards, surpassing pre-pandemic levels. By December 2022, there were approximately 40,000 and 60,000 additional new treatments for drugs used to treat hypercholesterolemia and hypertension, respectively, compared to the expected numbers based on 2018–2019 averages. The stratified analysis showed a relatively higher increase in less deprived quintiles. GP encounter activities mirrored trends in new antihypertensive and lipid-lowering initiations, with a significant reduction starting in March 2020 due to the first COVID-19 lockdown. Encounter rates gradually recovered from May 2020, reaching near pre-pandemic levels by March 2021. Notably, the encounter rate slopes during the reference period (2018–2019) and post-recovery phase (May 2021–December 2022) showed no significant difference [–0.7 (95% CI: −4.0, 2.5) vs. 0.9 (95% CI: −3.1, 4.9)].The observed increase in new treatments for drugs to treat hypercholesterolemia and hypertension suggests recovery of the healthcare system in Scotland following the COVID-19 pandemic. These higher prescribing rates post-pandemic hypothesise potential long-term sequelae associated with COVID-19. The findings demonstrate the potential for improved pharmacotherapy strategies that address both the backlog of untreated cases and new-onset conditions linked to COVID-19. This underscores the need for ongoing surveillance and flexible healthcare responses to manage emerging health challenges effectively. Additionally, our findings suggest novel research areas that could offer a more comprehensive understanding of the COVID-19 pandemic’s influence on the prescribing patterns of these widely used medications.

The Montana COVID-19 Case and Test Data web service hosts COVID-19 statistics for the state of Montana by county. The data was derived from local health officials at the county level who reported cases to the Montana Department of Health and Human Services. DPHHS tabulated case data and then gave the data to the Montana State Library to publish through this web service. The daily updates were managed by the Disaster and Emergency Service State Emergency Coordination Center. The feature service is comprised of Montana's county geography with attributes that summarize Total COVID-19 cases by age (10-year groups), by sex (M/F/U), new cases, total deaths, hospitalization count, total recovered and the number of total active cases. The two tables store various stats that include the total number of tests completed, and the number of new tests completed for individual test dates; and individual case data which includes age group, sex, county or residence and recovery status. Montana public health agencies and the Governor's Coronavirus task Force actively worked to limit the spread of novel coronavirus in Montana. The Montana State Library aided this effort by geo-enabling public health information and emergency response data to help decision-makers, State Emergency Coordination Center and the Governor's Coronavirus Task Force understand the spread of the disease. This data and feature service is no longer maintained and the final update to this data was made on 05/05/2023.

CRA composite indices by airport network under COVID-19.

The epidemic measures (computed on the day PAUSE started) are: cumulative incidence for each county (CI, columns 1 and 2); percent cumulative incidence (%CI, columns 3 and 4); daily incidence (DI, columns 5 and 6); percent daily incidence (%DI, columns 7 and 8). The first row shows the correlations of these epidemic measures with the lowest traffic level (which occurred briefly after the start of PAUSE), as a fraction of the original traffic baseline. The other three rows show the corresponding correlations with the lowest mobility to Retail, Grocery and Workspace (as a fraction of the baseline). The corresponding significance values are shown as separate columns. The correlations with daily incidence DI and %DI were based on values from the window smoothed time series; the corresponding correlations based on raw time series were very similar.

Content

District-wise Covid-19 data of Maharashtra, a state in India as on August 25, 2021. The data include number of positive cases, active cases, recovered, deceased cases, recovery rate and fatality rate.

Attribute Information

Cumulative Cases by Districts

1. Districts - Name of districts in Maharashtra, India
2. Positive Cases - Number of positive cases
3. Active Cases - Number of active cases
4. Recovered - Number of recovered cases
5. Deceased - Number of deaths
6. Recovery Rate (%) - Ratio of number of recovered cases to positive cases
7. Fatality Rate (%) - Ratio of number of deaths to positive cases

Source

Link : https://www.covid19maharashtragov.in/mh-covid/dashboard